Vijaya Diagnostic Centre (VIJAYA) Q4 19/20 earnings summary

Executive summary

• FY20 growth continued until late-year COVID-19 disruption; standalone revenue rose 17.8% YoY to ₹328.65 crore and PAT grew 25% to ₹61.24 crore.

• Network comprised 78+ centres across 12 cities; 13 centres opened during the year, with footfalls up 19% and tests up 15% YoY.

Financial highlights

• Consolidated revenue was ₹338.82 crore, up 15.8% YoY; PBT reached ₹83.43 crore, up 16.8%, and PAT was ₹62.78 crore versus ₹49.69 crore.

• Standalone revenue was ₹328.65 crore versus ₹279.08 crore; PBT was ₹81.75 crore versus ₹70.41 crore, and PAT was ₹61.24 crore versus ₹48.92 crore.

• Consolidated basic EPS was ₹138.59 versus ₹109.10; diluted EPS was ₹137.94 versus ₹108.74.

• FY20 EBITDA was reported at ₹115.70 crore, up 23% YoY; standalone EBITDA margin was 40.30% versus 33.73% in the financial performance table.

Outlook and guidance

• Growth priorities include digital initiatives, online presence, home sample collection, test-menu expansion, and identifying suitable inorganic opportunities for geographic growth.

• Further investment in selected modalities, inland laboratories near larger centres, and network infrastructure is planned; management emphasized volume growth and cost optimization.

• COVID-19 testing services were offered across diagnostic centres, while management expected FY21 to be challenging amid pandemic disruption.